Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density

Atossa Therapeutics

Status and phase: Active, not recruiting; Phase 2

Conditions: Breast Density

Treatments: Drug: Placebo; Drug: Z-Endoxifen

Study type: Interventional

Funder types: Industry

Identifiers

NCT05068388

ATOS-016R

Details and patient eligibility

About

This is a randomized, double-blinded, placebo-controlled dose-response efficacy study of oral (Z)-endoxifen in premenopausal women with measurable breast density. There will be 5 in-clinic visits (Screening, Day 1, Months 1, 3 and 6) and 3 self-report visits (Months 2, 4 and 5). Standard of care mammograms will be used for the screening mammogram as well as the 24-month follow up visit.

Enrollment: 240 patients

Sex: Female

Ages: 40 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Premenopausal women (defined as having at least one menstruation during the prior 12 months; women with an intrauterine device are considered premenopausal if <52 years)
2. Women of childbearing potential using a highly effective method of birth control* throughout the study period and willing to comply with monthly pregnancy testing
3. Screening mammogram performed within 3 month of study inclusion
4. Mammographic density assessed as BI-RADS® score B, C, or D
5. Must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects

Exclusion criteria

1. Mammographic BI-RADS® malignancy code ≥3 at baseline mammography

2. Any previous diagnosis of breast cancer, including carcinoma in situ, or any other cancer (non-melanoma skin cancer and in situ cancer of the cervix are not exclusion criteria)

3. A history of breast surgery, e.g., reduction or enlargement, which might affect mammographic density measurements

4. Current medical conditions:

   1. APC (activated protein C) resistance, an inherited coagulation disorder
   2. Systolic pressure higher than 160 mm Hg or diastolic higher than 100 mm Hg
   3. Cataract(s)
   4. Uncontrolled diabetes (defined as HbA1c >50 mmol/mol)
   5. Abnormal lab values deemed clinically significant by Investigator

5. BMI > 30

6. Women who have an increased risk of venous thrombosis due to immobilization, e.g., using wheelchair

7. Agents that have the potential to decrease endoxifen levels through increased metabolic clearance:

   1. Certain anti-epileptic therapies (carbamazepine, fenytoin, fenobarbital, lamotrigine)
   2. Certain antibiotics (rifamycins)
   3. St John's wort (in Swedish: johannesört)
   4. Certain HIV medications (efavirenz, ritonavir)

8. Lactating, pregnant, or plan to become pregnant in the next year

9. History of thromboembolic disease such as embolus, deep vein thrombosis, stroke, TIA (transient ischemic attack) or myocardial infarction

10. Allergy to endoxifen or any of its components

11. Previous treatment with an anti-oestrogen, including experimental drug studies (e.g., Karma CREME, Karisma-1 or Karisma-2)

12. Prescribed and regular use of anticoagulants (defined as substances included in group B01A in the ATC-system)

13. Participation in another investigational clinical trial in the last 6 months

14. Not willing or able to understand the study information and/or informed consent

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

240 participants in 3 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

oral capsule

Treatment:

Drug: Placebo

1 mg (Z)-endoxifen

Experimental group

Description:

oral capsule

Treatment:

Drug: Z-Endoxifen

2 mg (Z)-endoxifen

Experimental group

Description:

oral capsule

Treatment:

Drug: Z-Endoxifen